Wells Fargo analyst Stephen Baxter raised the firm’s price target on BrightSpring Health (BTSG) to $39 from $33 and keeps an Overweight rating on the shares following Q3 earnings. The firm is also raising its estimates for pharmacy strength. Wells increased its EBITDA growth rate for 2026 to 15% from 11% previously due to annualizing strong second half of 2025 and a generally durable view of fundamentals.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTSG:
- BrightSpring Health price target raised to $40 from $32 at Morgan Stanley
- BrightSpring Health Services Shines in Q3 Earnings Call
- BrightSpring Health price target raised to $38 from $32 at Mizuho
- BrightSpring Health price target raised to $41 from $30 at BTIG
- BrightSpring Health price target raised to $42 from $35 at UBS